

CONFIDENTIAL

25<sup>th</sup> July 2008



Dr Carole Longson  
Director  
Centre for Health Technology Evaluation  
National Institute for Health and Clinical Excellence  
MidCity Place  
71 High Holborn  
London WC1V 6NA

Dear Dr Longson,

**NICE consultation – Use of tumour necrosis factor alpha (TNF a) inhibitors  
(adalimumab, and infliximab [review]) for Crohn's disease**

Thank you for your letter of 30<sup>th</sup> June 2008 requesting comments on the ACD and evaluation report of the above Technology Appraisal. Sanofi-aventis have no comments at this time but are grateful for the opportunity to comment on this appraisal.

Should you require any further clarification please feel free to contact me.

Regards,

[Redacted signature]

[Redacted name]

Health Outcomes  
sanofi-aventis UK  
One Onslow Street  
Guildford, GU1 4YS

T: [Redacted]  
F: [Redacted]

[Redacted]@sanofi-aventis.com